EUVIMEDOpdag EUVIMED
Crossref

Effects of RS17053 on α 1 ‐adrenoceptors in rat vas deferens and aorta

Hadeel A Alsufyani iD, James R Docherty iD

Fundamental & Clinical Pharmacology · 2023

DOI: 10.1111/fcp.12930 ↗

At a glance

Journal article in Fundamental & Clinical Pharmacology, 2023. Written by Hadeel A Alsufyani and 1 co-authors. Institution: Department of Physiology, King Abdulaziz University, Jeddah, Saudi Arabia. Major MEDLINE topics: Prazosin, Vas Deferens. Cited 1 times so far (Crossref); 22 references. Funded by: Deanship of Scientific Research, King Abdullah University, Jeddah.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

RS17053 is classed as an α 1A ‐adrenoceptor selective antagonist.

Objectives

We have examined its profile of action at all subtypes of α 1 ‐adrenoceptor.

Methods

Noradrenaline (NA) evoked contractions of rat vas deferens involve α 1D ‐adrenoceptors in phasic contractions and α 1A ‐adrenoceptors in tonic contractions. Contractions of rat aorta to NA involve α 1D ‐ and α 1B ‐adrenoceptors.

Results

RS17053 (10 −5 M) shifted NA potency and virtually abolished tonic contractions to NA, with little or limited effect on phasic contractions. The α 1D ‐adrenoceptor antagonist BMY7378 (3 × 10 −7 M) significantly inhibited the remaining phasic component of the contractions, and the α 1A ‐adrenoceptor antagonist RS100329 (10 −7 M) inhibited further the residual tonic contraction. Hence, RS17053 shows high selectivity for α 1A ‐adrenoceptors over α 1D ‐adrenoceptors in rat vas deferens. However, RS17053 (10 −5 M) produced a large shift in the potency of NA in rat aorta, with a pK B of 6.82. Large shifts of NA potency in rat aorta involve α 1B ‐adrenoceptor blockade.

Conclusion

Results in rat vas deferens demonstrate low potency of RS17053 at α 1D ‐adrenoceptors, but results from rat aorta can only be explained as demonstrating α 1B ‐adrenoceptor antagonism by RS17053. RS17053 may be a useful pharmacological tool when reclassified as a mainly α 1A ‐ and to a lesser extent α 1B ‐adrenoceptor antagonist with little effect at α 1D ‐adrenoceptors.

Subjects

MeSH terms (MEDLINE)

PrazosinVas DeferensMaleRatsAnimalsReceptors, Adrenergic, alpha-1NorepinephrineAorta

Author keywords

BMY7378RS100329RS17053rat aortarat vas deferensα1A-adrenoceptorα1B-adrenoceptorα1D-adrenoceptor

Substances

PrazosinReceptors, Adrenergic, alpha-1Norepinephrine

Authors and institutions

  • Department of Physiology, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Department of Physiology, Royal College of Surgeons in Ireland, Dublin, Ireland.

ORCID profiles: Hadeel A Alsufyani, James R Docherty

Funding

  • Deanship of Scientific Research, King Abdullah University, Jeddah

Cite

APA

Alsufyani, H. A., & Docherty, J. R. (2023). Effects of RS17053 on α 1 ‐adrenoceptors in rat vas deferens and aorta. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.12930

Vancouver

Alsufyani HA, Docherty JR. Effects of RS17053 on α 1 ‐adrenoceptors in rat vas deferens and aorta. Fundamental & Clinical Pharmacology. 2023. doi:10.1111/fcp.12930

BibTeX
@article{Alsufyani2023,
  author = {Alsufyani, Hadeel A and Docherty, James R},
  title = {Effects of RS17053 on α 1 ‐adrenoceptors in rat vas deferens and aorta},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2023},
  doi = {10.1111/fcp.12930}
}
Start for free →